Related Experiment Videos
[Treatment of symptomatic bone metastases of prostatic carcinoma with strontium (Sr-89) chloride: initial experience]
F Mantovani1, S Minervini, G Malagola
1Ente Ospedaliero S. Carlo Borromeo, Divisione di Urologia, Milano.
Abstract:
Until now, patients with a progressive prostatic cancer, in whom all therapies failed and the disease spread locally and distally, was considered "a lost patient"; because it did not exist an effective therapy easily to be used. The skeletal pain control is a serious problem and it is a great responsibility also for the Urologists especially if the patient has not a short survival time and the quality of life very poor. Physicians feel the need for a systemic, well tolerated and effective therapy also for a long time, uniform and repeatable, able to be efficient for these patients. Strontium 89 chloride seems to offer all those possibilities and to be the best procedure for Urologist, Radiotherapists and Nuclear Specialists in order to satisfy the patients requirements. International research has shown Sr-89 Chloride is a powerful new therapy. Sr-90 Chloride is a radiopharmaceutical product for the treatment of painful metastases from prostatic cancer. It is a new treatment but its effectiveness is well documented and results are reported in the most important international literature. In our Department a clinical research has started and our purpose is to produce more data for a clinical and biological evaluation of the results hoping that a similar research will extend as a multicenter study.
Insights
Strontium 89 chloride offers a new, effective treatment option for advanced prostate cancer patients with widespread metastases. This therapy addresses skeletal pain and improves quality of life for previously untreatable cases.
Area of Science:
- Oncology
- Radiopharmaceuticals
- Nuclear Medicine
Background:
- Progressive prostate cancer with widespread metastases presents significant treatment challenges, particularly regarding skeletal pain and quality of life.
- Existing therapies often fail in advanced stages, leaving patients with limited options and unmet medical needs.
- Urologists and oncologists require well-tolerated, effective, and repeatable systemic therapies for these difficult cases.
Purpose of the Study:
- To evaluate Strontium 89 chloride (Sr-89) as a therapeutic agent for patients with advanced prostate cancer and painful bone metastases.
- To assess the efficacy and tolerability of Sr-89 chloride in managing skeletal pain and improving quality of life.
- To gather clinical and biological data for a comprehensive evaluation of Sr-89 chloride treatment.
Main Methods:
- Clinical research initiated to investigate the use of Strontium 89 chloride.
- Focus on evaluating clinical and biological outcomes of the treatment.
- Data collection for a thorough assessment of treatment effectiveness.
Main Results:
- International research indicates Strontium 89 chloride is a powerful new therapy for painful metastases from prostate cancer.
- Effectiveness of Sr-89 chloride is well-documented in international literature.
- Sr-89 chloride is a radiopharmaceutical product specifically for treating painful metastases.
Conclusions:
- Strontium 89 chloride presents a promising therapeutic option for advanced prostate cancer patients with bone metastases.
- The therapy offers a systemic, well-tolerated, and effective solution for pain control and quality of life improvement.
- Further multicenter studies are encouraged to expand the clinical and biological evaluation of Sr-89 chloride.